Actinium-225

Actinium-225 is a neutron-rich isotope with 89 protons and a physical half-life of about 9.92 days.¹ It decays primarily by alpha emission through a short-lived chain that includes francium-221, astatine-217, and bismuth-213 before reaching stable lead-209. The chain yields several alpha particles, concentrating substantial energy in a small volume.

Alpha particles are helium nuclei with high linear energy transfer, meaning that they produce dense ionization along tracks only tens of micrometres long in tissue. This combination—multiple emissions, potent local damage, and a half-life compatible with manufacture and biological targeting—makes Actinium-225 valuable for radionuclide therapy. Its daughter products also require attention because some can redistribute after the original decay.

Targeted alpha-particle therapy attaches Actinium-225 to a molecule that recognizes a cancer-associated antigen or receptor. The carrier may be an antibody, peptide, small molecule, or other ligand; a chemical chelator holds the metal and is connected to that targeting structure. After administration, the conjugate is intended to accumulate at tumor sites and deliver alpha radiation close to malignant cells.

Dense ionization can cause irreparable DNA double-strand breaks and may kill cells that are relatively resistant to some conventional treatments. Investigational examples include Actinium-225 linked to prostate-specific membrane antigen ligands for metastatic castration-resistant prostate cancer and antibody-based constructs studied in hematologic malignancies. Clinical development remains dependent on dose selection, biodistribution, manufacturing quality, and careful monitoring of marrow and kidney toxicity.

Actinium-225 is scarce because demand for clinical research exceeds the output of traditional production routes. Historically, an Actinium-225 source has been obtained from thorium-229 generators, while accelerator-based methods can irradiate radium-226 or thorium targets; high-energy proton irradiation of thorium also produces actinium through spallation reactions. Each route presents different challenges involving target availability, unwanted isotopes, processing time, and radioactive-waste management.

Radiochemistry must separate Actinium-225 from chemically similar decay products and bind it rapidly to a stable chelator. DOTA-based ligands have been widely investigated, but the long-lived daughter sequence places special demands on complex stability: a daughter released from the chelator can expose healthy tissues to radiation. International isotope-supply programs therefore combine accelerator production, generator research, purification, and standardized quality control.¹

Actinium-225 therapy is governed by the behavior of an entire decay family, not only by the first alpha emission. Bismuth-213, one daughter in the chain, has a half-life of about 46 minutes and can emit either an alpha particle or a beta particle before the sequence reaches stable lead-209. Daughter recoil can physically dislodge a daughter nucleus from its original chelator, creating a radiobiological problem distinct from ordinary drug release.

The isotope’s short half-life is both an advantage and a logistical constraint: it permits treatment within a clinically useful interval but makes shipping, scheduling, and centralized production more difficult than for longer-lived radionuclides. Another niche application is the use of Actinium-225 as a parent nuclide in generator concepts intended to supply bismuth-213. Research also examines combination treatments, including immune-modulating approaches, although these remain investigational rather than established standards of care.

Alpha particle

A helium-4 nucleus emitted in some radioactive decays; it has high energy deposition over a very short path in tissue.

Targeted alpha-particle therapy

A radionuclide treatment that delivers alpha radiation to selected cells through a molecular targeting agent.

Chelator

A molecule that binds a metal ion, such as actinium, within a coordination complex.

Linear energy transfer

The energy deposited by ionizing radiation per unit distance as it travels through matter.